Sponsors (76)
The bill improves vaccine access, speed, consistency, and transparency by elevating ACIP recommendations and preserving compensation protections, but does so at the cost of higher public/private spending and reduced administrative flexibility that could slow adjustments and raise safety and conflict‑of‑interest risks.
Insured Americans gain guaranteed coverage for ACIP‑recommended vaccines because group health plans and insurers must cover immunizations that have an ACIP recommendation.
Patients (including children and people with chronic conditions) get faster public guidance on newly licensed vaccines because ACIP must consider new vaccines at its next meeting and issue recommendations within 90 days of notification.
Hospitals, patients, and the public receive clearer, evidence‑based vaccine guidance because ACIP recommendations are codified and the Director must publicly document scientific reasons for any deviation.
Taxpayers, employers, insurers, and insured individuals may face higher public and private costs because mandated coverage of all ACIP‑recommended vaccines, the bill's annual authorization, and potential legal/administrative expenses increase spending.
Federal and state public‑health officials (including the Secretary/Director) may have reduced flexibility to respond to real‑time operational needs or rapidly change policy during emergencies because ACIP recommendations are largely codified and the evidentiary bar for changing the Vaccine Injury Table is raised.
Patients and children could face safety risks because strict deadlines and public meeting requirements (e.g., 90‑day recommendation timelines) might pressure ACIP to issue guidance before longer‑term safety or effectiveness data are available.
Based on analysis of 3 sections of legislative text.
Codifies ACIP, applies Federal Advisory Committee Act rules, requires evidence‑based recommendations be adopted by HHS unless rejected with published justification, and raises evidentiary standards for Vaccine Injury Table changes.
Introduced June 4, 2025 by Frank Pallone · Last progress June 4, 2025
Codifies the Advisory Committee on Immunization Practices (ACIP) into federal law, makes most Federal Advisory Committee Act rules apply to ACIP, and requires the committee to give evidence-based vaccine recommendations to the HHS Director. The Director must adopt ACIP recommendations unless he or she publishes a statement explaining why the recommendation is not supported by a preponderance of the best available peer‑reviewed scientific evidence; adopted recommendations must be posted publicly and reported to senior HHS officials. Raises the evidentiary standard for changing entries on the Vaccine Injury Table so that removal or other modification of a vaccine entry (or additions to the list of compensable conditions) must be supported by the preponderance of the best available scientific evidence, while preserving the Secretary's existing authority to add new vaccines to the Table under current law. The bill also sets timelines and notification requirements for consideration of newly licensed vaccines and certain vaccine designations.